Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sirnaomics Names China Partner for siRNA Therapeutic

publication date: Jun 23, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sirnaomics, located in Maryland, USA, has partnered with Guangdong Zhongsheng Pharmaceutical Co. to develop its small interfering RNA (siRNA) ocular neovascularization therapeutic. The partnership will seek to develop and commercialize STP601, a Sirnaomics siRNA candidate for treatment of diabetic retinopathy and age-related macular degeneration. Zhongsheng Pharma is committing 63 million RMB ($9.8 million) to the partnership, including upfront and milestone payments. More details....

Stock Symbol: (SZE: 002317)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
ChinaBio® Events

ChinaBio® Investor Forum
2013-Shanhai
September 4-5,2013
Shanghai, China


ChinaBio® Leadership Retraet
2013-Suzhou
October 24-25, 2013
Suzhou, China


ChinaBio® Investor Forum
2013-Wuhan
December 4-5,2013
Wuhan, China
>>More events...
Partner Events

China Medical Affairs Summit
  June 18-19, 2013
Shanghai, China


China Forum 2013
November 3, 2013
Vienna, Austria

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners